Literature DB >> 1392371

Recurrent parotid swelling in children: clinical features useful for differential diagnosis of Sjögren's syndrome.

T Hara1, M Nagata, Y Mizuno, Y Ura, M Matsuo, K Ueda.   

Abstract

Immunological evaluations were performed in 59 children with at least five episodes of parotid swelling. Autoantibody(ies) was transiently or persistently detected in 12 (20%) of 59 patients with recurrent parotitis. Three of the 12 children with autoantibodies were diagnosed as having Sjögren's syndrome. The mean age at onset of parotid swelling in Sjögren's syndrome was significantly higher than that of recurrent parotitis of unknown etiology. The present study and the review of the literature suggest that patients with the onset of parotid swelling at age five years or over deserve screening for underlying systemic immune disorders.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1392371     DOI: 10.1111/j.1651-2227.1992.tb12292.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  4 in total

1.  Autosomal dominant juvenile recurrent parotitis.

Authors:  E Reid; F Douglas; Y Crow; A Hollman; J Gibson
Journal:  J Med Genet       Date:  1998-05       Impact factor: 6.318

2.  Sjögren's syndrome associated with systemic lupus erythematosus.

Authors:  Mehmet Taşdemir; Chiar Hasan; Ayşe Ağbaş; Özgür Kasapçopur; Nur Canpolat; Lale Sever; Salim Çalışkan
Journal:  Turk Pediatri Ars       Date:  2016-09-01

3.  Primary Sjögren syndrome in the paediatric age: a multicentre survey.

Authors:  Rolando Cimaz; Annachiara Casadei; Carlos Rose; Jirina Bartunkova; Anna Sediva; Fernanda Falcini; Paolo Picco; Marco Taglietti; Francesco Zulian; Rebecca Ten Cate; Flavio R Sztajnbok; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Eur J Pediatr       Date:  2003-07-29       Impact factor: 3.860

Review 4.  Sjögren's syndrome in childhood.

Authors:  Nora G Singer; Ingrid Tomanova-Soltys; Robert Lowe
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.686

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.